- Royalty Pharma and OMERS Capital Markets (OMERS) recently committed $350 million in non-dilutive funding for BioCryst.
- BioCryst generated $120 million from their flagship product Orladeyo in FY2021 and raised guidance to a minimum of $250 million for FY2022.
- BioCryst has started enrollment of its first patients for the REDEEM-1 and REDEEM-2 pivotal trials, which is studying an oral Factor D inhibitor (BCX9930) for treatment of paroxysmal nocturnal hemoglobinuria.
- There is currently a 25.4 million share short position in BCRX.
For further details see:
Updated Guidance And Royalty Pharma Financing Demolish Short Thesis For BioCryst Pharmaceuticals